WE DO THINGS DIFFERENTLY,

enabling us to impact more lives

EXPAND OUR IMPACT

The strategic selection of novel therapeutic targets drives our unique pipeline-in-a-product strategy. By leveraging patient-centric insights and our expertise in hematology and immunology, we uncover new therapeutic avenues with high commercial potential and the opportunity to significantly improve patient health outcomes with best-in-class therapies.

Our scientific approach focuses on using patient samples to understand the biology and complexities of serious diseases. This approach enables us to capitalize on unique antibody therapeutics that have the potential to transform care for underserved patients and give them hope.

Each of our programs is designed to address multiple diseases and represents a pipeline-in-a-product opportunity.

Each of our programs is designed to address multiple diseases and represents a pipeline-in-a-product opportunity.

We are driven by the possibilities of novel biology.

Our team leverages our clinical experience and scientific capabilities to understand the novel biology of serious diseases. We focus on identifying unique, high-potential targets so that we can develop best-in-class antibody therapeutics.

We prioritize transformative patient outcomes.

Patients are at the core of our mission and our scientific program, influencing every aspect of our therapeutic development. Patient experiences and outcomes drive continuous improvements in our treatment protocols and therapeutic approaches.

We do not let unknowns deter our focus.

Many diseases have limited data demonstrating disease course and epidemiology, which can be a barrier to developing treatments. We conduct natural history studies and partner with advocacy organizations to support proper diagnosis and enable all involved to appreciate the unmet need and value of treatment.

THANK YOU

We look forward to connecting with you